Option chain shows key data for Cocrystal Pharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Cocrystal Pharma.

Cocrystal Pharma (NASDAQ:COCP) Stock, Option Chain

Cocrystal Pharma

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

wall street chart shutter2

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ACAD

COCP

ONCO

SGMO

Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide

Crude Oil 6- logo

Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet

House,On,Stack,Coin,Growth,As,Chart,On,Wooden,Table

BDMD

WATT

US Stocks Open Higher; House Prices Increase In October

Cocrystal Pharma Inc

Press Releases

Cocrystal Pharma's Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins

Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections

Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025

Life Sciences Investor Forum Agenda Announced for March 13th

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference

Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants

AVCNF

BPTSY

CGTX

CSE:IZO

CSE:TELI

FBLG

HMTXF

IZOZF

LADX

NGENF

PDSB

RAFA

TELIF

TNXP

TSX:AVCN

TSXV:HEM

TSXV:NGEN

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Athira Pharma

Aytu BioPharma

Biofrontera

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cingulate

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Durect

Gelteq

Hoth Therapeutics

IGC Pharma

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lexaria Bioscience

Lipocine

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

ProPhase Labs

Pulmatrix

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Scilex Holding

Talphera

Traws Pharma

TherapeuticsMD

VYNE Therapeutics

HC Wainwright & Co.

Comments

Cocrystal Pharma

Cocrystal Pharma (COCP) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell